Analysts say the new mechanism would impact revenues in the short term only

The Indian pharmaceutical industry is likely to see a dip in valuations in the near term as a result of the recent pricing policy that aims to intensify the regulatory hold over essential drugs. Profit of major drug makers, including that of GlaxoSmithKline (GSK) Pharma, Abbott, Cipla, Ranbaxy and Cadila could be hit the most. But, analysts are optimistic that the revenue impact might not last for more than 18 months to two years.